Literature DB >> 29205080

The potential benefits from respiratory gating for breast cancer patients regarding target coverage and dose to organs at risk when applying strict dose limits to the heart: results from the DBCG HYPO trial.

Martin Berg1, Ebbe L Lorenzen2, Ingelise Jensen3, Mette S Thomsen4, Christina Maria Lutz4, Lasse Refsgaard1, Henrik D Nissen1, Birgitte V Offersen5.   

Abstract

PURPOSE: The potential benefits from respiratory gating (RG) compared to free-breathing (FB) regarding target coverage and dose to organs at risk for breast cancer patients receiving post-operative radiotherapy (RT) in the DBCG HYPO multicentre trial are reported.
MATERIAL AND METHODS: Patients included in the DBCG HYPO trial were randomized between 50 Gy in 25 fractions (normofractionated) versus 40 Gy in 15 fractions (hypofractionated). A tangential forward field-in-field dose planning technique was used to cover the clinical target volume (CTV) with the intent to limit dose to the left anterior descending coronary artery (LADCA) to 20 Gy and 17 Gy in the normo- and hypofractionated arms, respectively. Treatment plan data for 1327 patients from four Danish centres was retrospectively analyzed. FB right-sided patients served as control group for the left-sided patients regarding CTV V95% (relative volume receiving at least 95% of the prescribed dose), mean heart dose (MHD) and mean lung dose (MLD).
RESULTS: Median CTV V95% was for FB right-sided, FB left-sided and RG left-sided patients 94.6, 92.6 and 94.7% for normofractionated therapy, respectively, and 94.6, 91.8 and 94.4% for hypofractionated therapy and did not differ significantly for RG left-sided plans compared to FB right-sided in either study arm. CTV V95% was significantly lower for FB versus RG for left-sided plans in both arms. Median MHD was 0.7, 1.8 and 1.5 Gy (normofractionated therapy) versus 0.6, 1.5 and 1.2 Gy (hypofractionated therapy), respectively. The corresponding median MLD was 9.0, 8.3 and 7.3 Gy versus 7.3, 6.4 and 5.8 Gy, respectively.
CONCLUSIONS: RG for left-sided breast cancer patients ensured similar CTV V95% as for FB right-sided patients. MLD was lower for RG due to the increased lung volume. MHD was generally low due to strict protocol-defined maximum dose to LADCA, but for left-sided patients RG led to significantly lower MHD.

Entities:  

Mesh:

Year:  2017        PMID: 29205080     DOI: 10.1080/0284186X.2017.1406139

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  9 in total

Review 1.  Hypofractionated radiation treatment in the management of breast cancer.

Authors:  Apar Gupta; Nisha Ohri; Bruce G Haffty
Journal:  Expert Rev Anticancer Ther       Date:  2018-06-26       Impact factor: 4.512

2.  Deep inspiration breath-hold intensity modulated radiation therapy in a large clinical series of 239 left-sided breast cancer patients: a dosimetric analysis of organs at risk doses and clinical feasibility from a single center experience.

Authors:  Alessandro Testolin; Stefano Ciccarelli; Giulia Vidano; Rossella Avitabile; Francesca Dusi; Filippo Alongi
Journal:  Br J Radiol       Date:  2019-07-18       Impact factor: 3.039

3.  Helical tomotherapy with a complete-directional-complete block technique effectively reduces cardiac and lung dose for left-sided breast cancer.

Authors:  Hsin-Pei Yeh; Yu-Chuen Huang; Li-Ying Wang; Pei-Wei Shueng; Hui-Ju Tien; Chiu-Han Chang; San-Fang Chou; Chen-Hsi Hsieh
Journal:  Br J Radiol       Date:  2020-01-21       Impact factor: 3.039

4.  The relationship between radiation doses to coronary arteries and location of coronary stenosis requiring intervention in breast cancer survivors.

Authors:  Anna-Karin Wennstig; Hans Garmo; Ulf Isacsson; Giovanna Gagliardi; Niina Rintelä; Bo Lagerqvist; Lars Holmberg; Carl Blomqvist; Malin Sund; Greger Nilsson
Journal:  Radiat Oncol       Date:  2019-03-07       Impact factor: 3.481

5.  Deep inspiration breath hold reduces the mean heart dose in left breast cancer radiotherapy.

Authors:  Michał Falco; Bartłomiej Masojć; Agnieszka Macała; Magdalena Łukowiak; Piotr Woźniak; Julian Malicki
Journal:  Radiol Oncol       Date:  2021-01-29       Impact factor: 2.991

6.  Evaluation of the dosimetric and radiobiological parameters in four radiotherapy regimens for synchronous bilateral breast cancer.

Authors:  Sang-Won Kang; Seonghee Kang; Boram Lee; Changhoon Song; Keun-Yong Eom; Bum-Sup Jang; In Ah Kim; Jae-Sung Kim; Woong Cho; Dong-Suk Shin; Jin-Young Kim; Jin-Beom Chung
Journal:  J Appl Clin Med Phys       Date:  2022-06-21       Impact factor: 2.243

7.  Conventional Versus Different Hypofractionated Radiotherapy Dosage Schedules in Postmastectomy Advanced Breast Cancer.

Authors:  Neeraj Jain; Ramita Sharma; Kanchan Sachdeva; Amandeep Kaur; Meena Sudan
Journal:  J Med Phys       Date:  2022-08-05

Review 8.  Cardiotoxicity of Radiation Therapy: Mechanisms, Management, and Mitigation.

Authors:  P Ell; J M Martin; D A Cehic; D T M Ngo; A L Sverdlov
Journal:  Curr Treat Options Oncol       Date:  2021-06-10

9.  Dose constraints for whole breast radiation therapy based on the quality assessment of treatment plans in the randomised Danish breast cancer group (DBCG) HYPO trial.

Authors:  M S Thomsen; M Berg; S Zimmermann; C M Lutz; S Makocki; I Jensen; M H B Hjelstuen; S Pensold; M P Hasler; M-B Jensen; B V Offersen
Journal:  Clin Transl Radiat Oncol       Date:  2021-04-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.